PolyPid polypid.com


PolyPid is a clinical stage specialty pharmaceutical company, developing, manufacturing and commercializing products based on a platform named PLEX (Polymer-Lipid Encapsulation matriX), in the field of extended release, local drug delivery. PLEX technology optimizes drug therapeutic performance and clinical outcomes, improves pharmacoeconomic potential as well as offers lifecycle extension for drugs. This is achieved via PLEX based protected drug reservoirs enabling prolonged delivery of drugs, ...Show all

PolyPid is a clinical stage specialty pharmaceutical company, developing, manufacturing and commercializing products based on a platform named PLEX (Polymer-Lipid Encapsulation matriX), in the field of extended release, local drug delivery. PLEX tech...Show all

Company (Alive / Active)

Phone: +972-74-719-5700

Fax:

18 Hasivim Street

Petah Tikva, 4959376
Israel

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
PolyPid $46.7M Nov 7, 2018
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related PolyPid Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 5 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Chiasma

Newton, Massachusetts, United States
IPO / Went publicChiasma (NASDAQ: CHMA) is a biopharmaceutical company dedicated to improving the lives of patients with rare diseases by developing and commercializing oral medications that were previously available by injection only. The company's lead candidate is octreotide capsules, which has received orphan drug designation from the FDA and EMA. Chiasma is evaluating additional proteins, peptides and small molecule drugs that that are currently only available by injection but could potentially be converted...Show allLogin to see details

Glycologic

United Kingdom
Alive / ActiveGlycologic Limited is a company dedicated to the creation of nutritional, clinical nutrition and drug delivery systems based on carbohydrates which overcome the limitations of other technologies. The Company utilises the properties of carbohydrates to develop customised solutions to a wide variety of nutritional and pharmaceutical problems.Login to see details
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Sustained-release nucleic acid matrix compositions Aug 04, 2014 Apr 11, 2017 Patent
Sustained-release drug carrier composition Oct 26, 2014 Aug 23, 2016 Patent
Compositions and methods for the treatment of bone voids and open fractures Aug 01, 2013 Nov 03, 2015 Patent
Sustained-release drug carrier composition Jul 14, 2010 Mar 31, 2015 Patent
Sustained-release drug carrier composition Jul 14, 2009 Nov 04, 2014 Patent
See all 12 patents